Abstract
AN explanation of the intracellular mechanism by which sulphonylureas such as tolbutamide and chlorpropamide stimulate the release of insulin from the pancreas1,2 (as in the treatment of diabetes mellitus) should also account for certain effects of these materials outside the pancreas3–5. These include the effect of chlorpropamide in reducing polyuria in patients with diabetes insipidus4 and the possible involvement of tolbutamide in the increased cardiac mortality of patients treated with the drug5. It has been clear for some years that cyclic AMP (cyclic adenosine 3′,5′-monophosphate) plays an important part in the regulation of insulin secretion. For example, cyclic AMP causes the release of insulin from pancreas tissue in vitro6. Further, glucagon increases cyclic AMP activity in islet cells by activating the enzyme adenyl cyclase7, and theophylline increases cyclic AMP activity by inhibiting phosphodiesterase8,9. It is known that the sulphonylureas can influence the activity of cyclic AMP10,11, and tolbutamide and chlorpropamide inhibit the enzyme phosphodiesterase in the rat kidney12. We have now shown that the sulphonylureas may regulate the levels of cyclic AMP not merely in islet cells but in kidney, lung, heart and brain. In particular, the sulphonylureas, like the methylxanthines, inhibit the activity of cyclic AMP phosphodiesterase, which hydrolyses cyclic AMP to 5′-AMP8,9, which provides a plausible explanation for their effects in the pancreas and elsewhere.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Yalow, R. S., Black, H., Villazon, M., and Berson, S. A., Diabetes, 9, 356 (1960).
Coore, H. G., and Randle, P. J., Biochem. J., 93, 66 (1964).
Feldman, J. M., and Lebovitz, H. E., Arch. Intern. Med., 123, 314 (1969).
Meinders, A. E., Touber, J. L., and DeVries, L. A., Lancet, ii, 544 (1967).
Meinert, C. L., Knatterud, G. L., Prout, T. E., and Klimt, C. R., Diabetes, 19, 789 (1970).
Malaisse, W. J., Malaisse-Lagae, F., and Mayhew, D. A., J. Clin. Invest., 46, 1724 (1967).
Turtle, J. R., and Kipnis, D. M., Biochem. Biophys. Res. Commun., 28, 797 (1967).
Turtle, J., Littleton, C., and Kipnis, D., Nature, 213, 727 (1967).
Ensinck, J. W., Stoll, R. W., Gale, C. C., Santen, R. J., Touber, J. L., and Williams, R. H., J. Clin. Endocrinol., 31, 153 (1970).
Beck, M. P., Feld, J. B., and Davis, B., Clin. Res., 18, 494 (1970).
Fichman, M., and Brooker, G., Clin. Res., 18, 121 (1970).
Brooker, G., and Fichman, M., Biochem. Biophys. Res. Commun., 42, 824 (1971).
Sodoyez, J. C., Sodoyez-Goffaux, F., Lefebvre, P. J., and Foa, P. P., Acta Diab. Latina, 5, 86 (1968).
Krishna, G., Weiss, B., and Brodie, B. B., J. Pharmacol. Exp. Ther., 163, 379 (1968).
Creutzfeldt, W., Andreu-Kern, F., and Discher, R., Ann. NY Acad. Sci., 82, 537 (1959).
Beavo, J. A., Rogers, N. L., Crofford, O. B., Hardman, J. G., Sutherland, E. W., and Newman, E. V., Mol. Pharmacol., 6, 597 (1970).
Honda, F., and Hitomi, J., Biochim. Biophys. Acta, 161, 267 (1968).
Moore, P. F., Ann. NY Acad. Sci, 150, 256 (1968).
Triner, L., Vulliemoz, Y., Schwartz, I., and Nahas, G. G., Biochem. Biophys. Res. Commun., 40, 64 (1970).
Mandel, L. R., and Kuehl, F. A., Biochem. Biophys. Res. Commun., 28, 13 (1967).
Chan, S. S., and Fain, J. N., Mol. Pharmacol., 6, 513 (1970).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
GOLDFINE, I., PERLMAN, R. & ROTH, J. Inhibition of Cyclic 3′,5′-AMP Phosphodiesterase in Islet Cells and Other Tissues by Tolbutamide. Nature 234, 295–297 (1971). https://doi.org/10.1038/234295a0
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1038/234295a0
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.